Nothing Special   »   [go: up one dir, main page]

HUE048044T2 - 5-((Halofenil)-3-halo-piridin-2-il)-nitril-származékok, mint intermedierek az [(5-(halofenil)-3-hidroxipiridin-2-karbonil)-amino]-alkánsav-származékok elõállításához - Google Patents

5-((Halofenil)-3-halo-piridin-2-il)-nitril-származékok, mint intermedierek az [(5-(halofenil)-3-hidroxipiridin-2-karbonil)-amino]-alkánsav-származékok elõállításához

Info

Publication number
HUE048044T2
HUE048044T2 HUE17191362A HUE17191362A HUE048044T2 HU E048044 T2 HUE048044 T2 HU E048044T2 HU E17191362 A HUE17191362 A HU E17191362A HU E17191362 A HUE17191362 A HU E17191362A HU E048044 T2 HUE048044 T2 HU E048044T2
Authority
HU
Hungary
Prior art keywords
halophenyl
derivatives
hydroxypyridine
pyridin
intermediates
Prior art date
Application number
HUE17191362A
Other languages
English (en)
Inventor
Christopher Lanthier
Boris Gorin
Jan Oudenes
Craig Dixon
Alan Lu
James Copp
John Janusz
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of HUE048044T2 publication Critical patent/HUE048044T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE17191362A 2011-06-06 2012-06-05 5-((Halofenil)-3-halo-piridin-2-il)-nitril-származékok, mint intermedierek az [(5-(halofenil)-3-hidroxipiridin-2-karbonil)-amino]-alkánsav-származékok elõállításához HUE048044T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06

Publications (1)

Publication Number Publication Date
HUE048044T2 true HUE048044T2 (hu) 2020-05-28

Family

ID=47262177

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE19214405A HUE057571T2 (hu) 2011-06-06 2012-06-05 Eljárás [(5-(3-klór-fenil)-3-hidroxi-piridin-2-karbonil)-amino]-ecetsav elõállítására 5-((3-klór-fenil)-3-klór-piridin-2-il)-nitrilbõl kiindulva, és eljárás 5-(halogén-fenil)-3-halogén-piridin-2-il)-nitril-származékok elõállítására
HUE12796374A HUE026096T2 (hu) 2011-06-06 2012-06-05 Eljárás [(3-hidroxipiridin-2-karbonil)-amino]-alkánsavak, észterek és amidok elõállítására
HUE17191362A HUE048044T2 (hu) 2011-06-06 2012-06-05 5-((Halofenil)-3-halo-piridin-2-il)-nitril-származékok, mint intermedierek az [(5-(halofenil)-3-hidroxipiridin-2-karbonil)-amino]-alkánsav-származékok elõállításához
HUE15189822A HUE034975T2 (hu) 2011-06-06 2012-06-05 Karbonilamino alkánsavak, ezek észterei és amidjai elõállításához intermedierként alkalmazható 5-halogénfenil)-3-hidroxi-piridin-2-il)-karbonsav-származékok

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE19214405A HUE057571T2 (hu) 2011-06-06 2012-06-05 Eljárás [(5-(3-klór-fenil)-3-hidroxi-piridin-2-karbonil)-amino]-ecetsav elõállítására 5-((3-klór-fenil)-3-klór-piridin-2-il)-nitrilbõl kiindulva, és eljárás 5-(halogén-fenil)-3-halogén-piridin-2-il)-nitril-származékok elõállítására
HUE12796374A HUE026096T2 (hu) 2011-06-06 2012-06-05 Eljárás [(3-hidroxipiridin-2-karbonil)-amino]-alkánsavak, észterek és amidok elõállítására

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15189822A HUE034975T2 (hu) 2011-06-06 2012-06-05 Karbonilamino alkánsavak, ezek észterei és amidjai elõállításához intermedierként alkalmazható 5-halogénfenil)-3-hidroxi-piridin-2-il)-karbonsav-származékok

Country Status (24)

Country Link
US (6) US9145366B2 (hu)
EP (5) EP3683209B1 (hu)
JP (6) JP6290781B2 (hu)
KR (5) KR102000485B1 (hu)
CN (1) CN106518759B (hu)
AU (4) AU2012268426B2 (hu)
CA (2) CA2838194C (hu)
CY (4) CY1117177T1 (hu)
DK (4) DK3000808T3 (hu)
ES (4) ES2771232T3 (hu)
HK (3) HK1196616A1 (hu)
HR (4) HRP20211916T1 (hu)
HU (4) HUE057571T2 (hu)
IL (1) IL229775A (hu)
LT (3) LT3000808T (hu)
MX (2) MX337216B (hu)
NO (1) NO2686520T3 (hu)
PL (4) PL3000808T3 (hu)
PT (4) PT3000808T (hu)
RS (3) RS56580B1 (hu)
RU (2) RU2764667C2 (hu)
SI (4) SI3683209T1 (hu)
SM (3) SMT201700534T1 (hu)
WO (1) WO2012170377A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3357911T (lt) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolilo hidroksilazės inhibitoriai ir naudojimo būdai
NO2686520T3 (hu) * 2011-06-06 2018-03-17
BR112015031027A2 (pt) * 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) * 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CA2981176A1 (en) 2015-04-01 2017-10-06 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
ES2831863T3 (es) * 2016-12-13 2021-06-09 Crystal Pharmaceutical Suzhou Co Ltd Nuevas formas cristalinas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético y procesos de preparación de las mismas
IL269623B1 (en) * 2017-03-29 2025-01-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of HIF prolyl hydroxylase activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
WO2020217733A1 (ja) * 2019-04-26 2020-10-29 株式会社カネカ Ｖａｄａｄｕｓｔａｔ中間体の製造方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
WO2021117767A1 (ja) * 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
JPWO2021149724A1 (hu) 2020-01-24 2021-07-29
US20230286918A1 (en) * 2020-07-02 2023-09-14 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
CN118715015A (zh) 2021-12-17 2024-09-27 阿克比治疗有限公司 选择性phd1抑制剂化合物、组合物和使用方法
WO2024165507A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Use of hif-1α stabilizing agents for the treatment of type i interferonopathies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (hu) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
KR20000065090A (ko) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
PL344056A1 (en) 1998-03-23 2001-09-24 Aventis Pharm Prod Inc Piperididinyl and n-amidinopiperidinyl derivatives
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK2289531T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc Medications for the treatment or prevention of anemia
MXPA04011310A (es) 2002-05-17 2005-02-14 Celgene Corp Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
MXPA05002245A (es) * 2002-08-29 2005-06-08 Merck & Co Inc Derivados de n-biarilmetil aminocicloalcancarboxamida.
EP2156830A1 (en) 2002-10-16 2010-02-24 Isis Innovation Limited Modulators of asparaginyl hydoxylase activity of FIH
AU2003298611A1 (en) 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
BRPI0411055B1 (pt) 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
WO2005118836A2 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
TW200609218A (en) 2004-05-31 2006-03-16 Tanabe Seiyaku Co Bicyclic compounds
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
EP1919463B9 (en) 2005-06-15 2011-02-02 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
ES2446416T3 (es) 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
JP2009522383A (ja) 2006-01-09 2009-06-11 ビーティージー・インターナショナル・リミテッド 低酸素誘導因子−１の調節物質及び関連する使用
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
LT3357911T (lt) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolilo hidroksilazės inhibitoriai ir naudojimo būdai
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
EP2136810A4 (en) 2007-04-18 2012-01-04 Merck Sharp & Dohme NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
BRPI0812361A2 (pt) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese
JP5241718B2 (ja) 2007-08-06 2013-07-17 千寿製薬株式会社 ＨＩＦ−１αおよびＨＩＦ−２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
JP2010535855A (ja) 2007-08-10 2010-11-25 クリスタルゲノミクス、インク． ピリジン誘導体およびその使用方法
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
AU2008329746A1 (en) 2007-11-30 2009-06-04 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
NZ585701A (en) 2007-11-30 2012-09-28 Glaxosmithkline Llc Benzopyrazine derivatives as prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
HUE027249T2 (hu) * 2008-03-03 2016-10-28 Novartis Ag TLR aktivitás modulátor vegyületek és készítmények
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
MX2010010241A (es) * 2008-03-20 2010-12-06 Forest Lab Holdings Ltd Derivados de piperidina novedosos como inhibidores de estearoil-coa desaturasa.
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
BRPI0916233A2 (pt) 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
CA2755132C (en) * 2009-03-31 2018-02-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
IN2012DN04940A (hu) 2009-11-06 2015-09-25 Aerpio Therapeutics Inc
RU2602498C2 (ru) 2011-06-06 2016-11-20 Акебиа Терапеутикс Инк. Соединения и композиции для стабилизации индуцируемого гипоксией фактора-2 альфа как способ лечения рака
NO2686520T3 (hu) * 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2734504B1 (en) 2011-07-22 2016-09-14 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
CA2921005A1 (en) 2013-08-16 2015-02-19 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
RU2016133980A (ru) 2014-01-23 2018-03-01 Экебиа Терапьютикс, Инк. Композиции и способы для лечения заболеваний глаз
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CA2981176A1 (en) 2015-04-01 2017-10-06 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法

Also Published As

Publication number Publication date
JP2019123741A (ja) 2019-07-25
RS56580B1 (sr) 2018-02-28
DK2718265T3 (en) 2016-01-25
EP4026829A1 (en) 2022-07-13
JP6816195B2 (ja) 2021-01-20
MX2013014228A (es) 2014-03-26
KR102059366B1 (ko) 2019-12-26
HRP20151416T1 (hr) 2016-03-25
KR102000485B1 (ko) 2019-07-16
JP2021059573A (ja) 2021-04-15
US10246416B2 (en) 2019-04-02
AU2012268426A1 (en) 2014-01-09
HK1196616A1 (zh) 2014-12-19
KR20190032617A (ko) 2019-03-27
HRP20211916T1 (hr) 2022-03-18
CY1119605T1 (el) 2018-04-04
CA3135440A1 (en) 2012-12-13
AU2020204528A1 (en) 2020-07-30
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
LT3290404T (lt) 2020-02-25
US20210122715A1 (en) 2021-04-29
EP2718265B1 (en) 2015-12-16
HRP20171740T1 (hr) 2018-03-09
DK3290404T3 (da) 2020-02-17
DK3683209T3 (da) 2021-12-06
CN103717575A (zh) 2014-04-09
EP2718265A4 (en) 2014-11-19
KR102171315B1 (ko) 2020-10-28
KR102293016B1 (ko) 2021-08-26
PL3290404T3 (pl) 2020-06-01
LT3683209T (lt) 2022-01-10
HK1252109A1 (zh) 2019-05-17
EP3290404A1 (en) 2018-03-07
KR20140037192A (ko) 2014-03-26
EP3000808A1 (en) 2016-03-30
SMT201700534T1 (it) 2018-01-11
WO2012170377A1 (en) 2012-12-13
AU2017202414A1 (en) 2017-05-04
DK3000808T3 (da) 2017-11-27
EP2718265A1 (en) 2014-04-16
SMT202000061T1 (it) 2020-03-13
AU2012268426B2 (en) 2017-02-16
US9776969B2 (en) 2017-10-03
PL3000808T3 (pl) 2018-03-30
CA2838194C (en) 2022-01-11
JP7284309B2 (ja) 2023-05-30
CY1122639T1 (el) 2021-03-12
EP3290404B1 (en) 2019-12-11
JP2022081597A (ja) 2022-05-31
US20230002323A1 (en) 2023-01-05
AU2017202414B2 (en) 2018-07-19
PT3000808T (pt) 2017-11-23
US20190375713A1 (en) 2019-12-12
ES2900572T3 (es) 2022-03-17
ES2647602T3 (es) 2017-12-22
ES2559850T3 (es) 2016-02-16
PL3683209T3 (pl) 2022-02-21
CN106518759A (zh) 2017-03-22
PT2718265E (pt) 2016-02-15
SI3290404T1 (sl) 2020-03-31
KR20200121911A (ko) 2020-10-26
KR102032864B1 (ko) 2019-10-16
EP3683209A1 (en) 2020-07-22
PL2718265T3 (pl) 2016-04-29
US20170362178A1 (en) 2017-12-21
HRP20200197T1 (hr) 2020-05-15
NO2686520T3 (hu) 2018-03-17
PT3290404T (pt) 2020-02-19
JP2018111697A (ja) 2018-07-19
CY1124874T1 (el) 2022-11-25
HUE026096T2 (hu) 2016-05-30
US11267785B2 (en) 2022-03-08
SI3683209T1 (sl) 2022-03-31
PT3683209T (pt) 2021-12-15
HUE034975T2 (hu) 2018-05-02
CA2838194A1 (en) 2012-12-13
CY1117177T1 (el) 2017-04-05
AU2020204528B2 (en) 2022-07-14
KR20190031593A (ko) 2019-03-26
AU2018250355A1 (en) 2018-11-08
LT3000808T (lt) 2018-01-25
RU2764667C2 (ru) 2022-01-19
EP3683209B1 (en) 2021-11-10
KR20190141805A (ko) 2019-12-24
JP2014522409A (ja) 2014-09-04
JP2023103414A (ja) 2023-07-26
RU2016139352A (ru) 2018-12-13
ES2771232T3 (es) 2020-07-06
US20150361043A1 (en) 2015-12-17
US20120309977A1 (en) 2012-12-06
JP6290781B2 (ja) 2018-03-07
IL229775A (en) 2016-06-30
US10738010B2 (en) 2020-08-11
RS54517B1 (en) 2016-06-30
SMT201600013B (it) 2016-02-25
MX347709B (es) 2017-05-10
CN106518759B (zh) 2019-07-30
HUE057571T2 (hu) 2022-05-28
RU2016139352A3 (hu) 2020-01-27
HK1216173A1 (zh) 2016-10-21
EP3000808B1 (en) 2017-09-27
RU2013158640A (ru) 2015-07-20
AU2018250355B2 (en) 2020-04-09
NZ618570A (en) 2015-07-31
MX337216B (es) 2016-02-18
RU2602083C2 (ru) 2016-11-10
JP7039682B2 (ja) 2022-03-22
JP6510094B2 (ja) 2019-05-08
SI2718265T1 (sl) 2016-03-31
SI3000808T1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
HK1252109A1 (zh) 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile衍生物作為[(-5-(鹵代苯基)-3-羥基吡啶-2-羰基)-氨基]烷醇酸衍生物的製備中間體
HRP20181696T1 (hr) Postupak za pripremu dipeptidnih derivata lizin-glutaminske kiseline
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
IL232158A0 (en) N-terminally modified amino acid derivatives that can be used to form microspheres that surround a drug
PL2609071T3 (pl) Nowy sposób otrzymywania związków pośrednich użytecznych do wytwarzania inhibitorów NEP
HK1199649A1 (en) Process for the preparation of polyamides
IL227249A (en) Process for making sulfone dilution
SI2609075T1 (sl) Postopek za pripravo intermediatov za izdelavo NEP inhibitorjev
HK1200061A1 (en) Composition with improved digestibility of proteins
HK1194733A1 (zh) 製備 -酰基- -苯基磺酰基脯氨酰胺衍生物的方法及中間體
ZA201404246B (en) Process for the preparation of(5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-1yl)-acetic acid
IL231645A (en) Process for making isoxazolyl - methoxy - nicotinic acids
IL225680A0 (en) Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives
PL2593423T3 (pl) Proces wytwarzania środków kontrastowych
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
PT2673282T (pt) Processo inovador para a preparação de ácidos drónicos
PL396818A1 (pl) Sposób wytwarzania kwasów dialkiloaminometylo(hydroksymetylo)fosfinowych
PL396622A1 (pl) Pochodne diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych, sposób wytwarzania pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych oraz zastosowanie pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych
GB201104653D0 (en) Improvements in the manufacture of fatty acids